HT
AGIO icon

Headlands Technologies’s Agios Pharmaceuticals AGIO Stock Holding History

Headlands Technologies’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$772K Sell
20,805
-38,452
-65% -$1.17M 0.08% 302
2026
Q1 		$2M Buy
59,257
+6,518
+12% +$185K 0.23% 88
2025
Q4 		$1.44M Buy
+52,739
New +$1.85M 0.12% 209
2025
Q3 		– Sell
-12,644
Closed -$421K – 612
2025
Q2 		$421K Buy
12,644
+1,929
+18% +$58.5K 0.05% 341
2025
Q1 		$314K Sell
10,715
-16,021
-60% -$531K 0.04% 369
2024
Q4 		$879K Buy
26,736
+12,989
+94% +$610K 0.09% 239
2024
Q3 		$611K Buy
13,747
+2,297
+20% +$104K 0.07% 303
2024
Q2 		$494K Buy
+11,450
New +$413K 0.05% 282
2024
Q1 		– Sell
-8,893
Closed -$198K – 1224
2023
Q4 		$198K Sell
8,893
-144
-2% -$3.23K 0.06% 279
2023
Q3 		$224K Buy
9,037
+2,153
+31% +$57K 0.11% 186
2023
Q2 		$195K Buy
+6,884
New +$171K 0.06% 283

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Headlands Technologies's AGIO Position: Q2 2026 in Review

Headlands Technologies reduced its Agios Pharmaceuticals (AGIO) stake by 65% in Q2 2026, selling an estimated $1.17M and leaving 20,805 shares worth $772K. The position accounts for 0.08% of the portfolio, ranked #302.

Headlands Technologies first reported a position in AGIO in Q2 2023 and has held it in 11 quarters since. The position peaked at $2M in Q1 2026. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Headlands Technologies held 20,805 shares of Agios Pharmaceuticals worth $772K as of Q2 2026.
  • Headlands Technologies sold 38,452 Agios Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
  • Agios Pharmaceuticals made up 0.08% of Headlands Technologies's portfolio in Q2 2026, its #302 holding.
  • Headlands Technologies first reported a position in Agios Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • Headlands Technologies's Agios Pharmaceuticals position peaked at $2M in Q1 2026.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.